Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
-
Published:2019-01
Issue:
Volume:106
Page:144-159
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Prelaj Arsela,
Tay Rebecca,
Ferrara Roberto,
Chaput Nathalie,
Besse Benjamin,
Califano RaffaeleORCID
Funder
AstraZeneca
BMS
Boehringer Ingelheim
Lilly
Pfizer
Roche
Sanofi-Aventis
Servier
Onxeo
OncoMed
Inivata
OSE Pharma
Loxo
Subject
Cancer Research,Oncology
Reference152 articles.
1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015
2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015
3. Pembrolzumab versus docetaxel for previously treated, PD-L1 positive, advanced non-small-celllung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016
4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017
5. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Cited by
167 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献